Cancer Vaccine

Researchers find evidence of clinical activity in Tricom in advanced cancers

Published in Cancer Weekly, June 24th, 2003

Georgetown University researchers presented clinical data confirming the safety and the first evidence of clinical activity of Therion Biologics' Tricom therapeutic vaccines.

Proprietary to Therion, Tricom consists of three costimulatory molecules designed to optimize the immune response necessary for tumor destruction when delivered as part of the company's pox virus-based vaccines. This approach, delivered in a "prime-boost" dosing regimen, induced tumor-specific immune responses and significant clinical benefit in some patients with CEA-expressing cancers (in this study, predominantly gastrointestinal cancers).

Specifically, disease stabilization...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-06-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry